Gossamer Bio (GOSS) Sees Strong Analyst Confidence Amid Seralutinib Progress and Upcoming PROSERA Data

With strong 1-year returns and upside potential, Gossamer Bio, Inc. (NASDAQ:GOSS) secures a spot on our list of the 12 best multibagger stocks to buy heading into 2026. Gossamer Bio (GOSS) Sees Strong Analyst Confidence Amid Seralutinib Progress and Upcoming PROSERA Data Amid the company’s continued efforts to advance seralutinib across two late-stage pulmonary hypertension programs, analyst confidence in Gossamer Bio, Inc. (NASDAQ:GOSS) remains high. By the end of Q3 2025, Gossamer Bio, Inc. (NASDAQ:GO ...